Paid Clinical Trials Tennessee
Discover 1,814 paid clinical trials in Tennessee. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisA Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT06470048
Conditions
Diffuse Cutaneous Systemic Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Placebo
Ianalumab
Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor:
Genmab
Location:
Code:
NCT05579366
Conditions
Platinum-Resistant Ovarian Cancer
Platinum Sensitive Ovarian Cancer (PSOC)
High Grade Epithelial Ovarian Cancer
High Grade Serous Ovarian Cancer
Primary Peritoneal Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Rina-S
Carboplatin
Bevacizumab
Pembrolizumab
ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility TrialACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial
Sponsor:
Arthrex, Inc.
Location:
Code:
NCT05765266
Conditions
Knee Osteoarthritis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
ACP Max™
Depo-Medrol®
Bupropion to Reduce Cancer Related Fatigue in Cancer SurvivorsBupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Sponsor:
University of Rochester NCORP Research Base
Location:
Code:
NCT03996265
Conditions
Be Diagnosed With Cancer and Have Completed Systemic Therapy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bupropion Hydrochloride Controlled-release
Placebo Administration
Quality-of-Life Assessment
Questionnaire Administration
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSAn Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Sponsor:
XenoPort, Inc.
Location:
Code:
NCT02560766
Conditions
RLS
Eligibility Criteria
Sex: All
Age: 13 - 17
Healthy Volunteers: Not accepted
Interventions
HORIZANT 300 mg
HORIZANT 600 mg
Placebo
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and LymphomaTherapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Sponsor:
St. Jude Children's Research Hospital
Location:
Code:
NCT06533748
Conditions
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Eligibility Criteria
Sex: All
Age: 1 - 18
Healthy Volunteers: Not accepted
Interventions
Dexamethasone
Vincristine
Inotuzumab
Blinatumomab
Dasatinib
Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid TumorsSafety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Location:
Code:
NCT03398720
Conditions
Solid Tumor, Adult
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
HTI-1066 dose level 1
HTI-1066 dose level 2
HTI-1066 dose level 3
HTI-1066 dose level 4
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsA First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Sponsor:
AstraZeneca
Location:
Code:
NCT06188520
Conditions
ER+ HER2- Advanced Breast Cancer
High-grade Serous Ovarian Cancer (HGSOC)
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
AZD8421
Camizestrant
Ribociclib
Palbociclib
Abemaciclib
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06077760
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
V940
Pembrolizumab
Placebo
National Collaborative to Improve Care of Children With Complex Congenital Heart DiseaseNational Collaborative to Improve Care of Children With Complex Congenital Heart Disease
Sponsor:
Children's Hospital Medical Center, Cincinnati
Location:
Code:
NCT02852031
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Eligibility Criteria
Sex: All
Age: 0 - 15
Healthy Volunteers: Not accepted
Interventions
Collaborative Learning Network